Generalized Pustular Psoriasis Market Set to Transform as IL-36 Targeted Therapies Reshape Treatment Landscape Across 8MM Through 2036, Thelansis Reports

Thelansis releases an in-depth "Generalized Pustular Psoriasis (GPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036)," mapping how rapid-onset biologics, an FDA decision due later this year, and rising diagnostic awareness are set to redefine care for this rare, life-threatening skin disease across the US, EU5, Japan, and China.

Generalized Pustular Psoriasis is having a moment. For decades, this rare and potentially fatal autoinflammatory skin disorder had no dedicated therapy, patients in flare were managed with off-label steroids, retinoids, or cyclosporine, often in intensive care settings. That changed with the arrival of IL-36 receptor antagonists, and 2026 looks set to be the year the GPP market gets even more crowded, competitive, and commercially meaningful.
Thelansis's newly published report, "Generalized Pustular Psoriasis (GPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036)," gives pharma strategy, market access, and commercial teams a complete view of where this market is headed - patient numbers, drug-level forecasts, competitive positioning, and the regulatory catalysts that will decide who wins share over the next decade, across the US, Germany, France, Italy, Spain, UK, Japan, and China.

Request a free sample of Thelansis' Generalized Pustular Psoriasis (GPP) Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/generalized-pustular-psoriasis-gpp-market-outlook-forecast-2026-to-2036/

Executive Summary
• GPP is a rare, sterile pustular skin disease driven by unchecked IL-36 pathway signaling, frequently traced to loss-of-function mutations in IL36RN, with additional culprits in CARD14, AP1S3, and MPO.
• The disease is genetically and clinically distinct from plaque psoriasis, presenting with sudden flares of erythema, pustulation, fever, and systemic inflammation that can escalate to sepsis and organ dysfunction if untreated.
• The competitive landscape has moved from a single first-in-class entrant to a multi-player field, with a second IL-36-targeted biologic now awaiting an FDA verdict.
• Thelansis's report quantifies incidence, prevalence, and drug-treated populations across all 8MM, alongside a 10-year, patient-based revenue forecast validated against top-down methodology.
• Pricing, access, and positioning strategy will increasingly separate winners from also-rans as more IL-36 antagonists enter a market that, until recently, had none.

Key Emerging Players
• Vanda Pharmaceuticals - Imsidolimab: A fully humanized IgG4 monoclonal antibody targeting the IL-36 receptor. The FDA accepted Vanda's Biologics License Application, setting a PDUFA target action date of December 12, 2026 positioning, imsidolimab as the next major entrant into acute GPP care.
• Imsidolimab's filing rests on the pivotal GEMINI-1 and GEMINI-2 Phase III trials, where roughly half of treated patients reached clear or almost-clear skin by week four following a single infusion, with durable control sustained through an extended monthly-dosing maintenance phase.
• Beyond the lead late-stage candidate, an early-phase pipeline continues to explore complementary IL-36 and neutrophil-pathway approaches, reflecting sustained industry interest in a disease that remained a therapeutic blank space for years.
• The report profiles each emerging asset's trial data, likely launch timing, and positioning relative to existing standards of care, critical input for portfolio and in-licensing decisions.

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Generalized Pustular Psoriasis (GPP): https://thelansis.com/reports/generalized-pustular-psoriasis-gpp-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpp_mo

Key Current Therapies or Standard of Care
• Spesolimab (Spevigo, Boehringer Ingelheim/LEO Pharma) remains the benchmark, the first-in-class IL-36 receptor antagonist, approved for acute flares in adults and adolescents (12+, ≥40 kg) via IV infusion, and for maintenance therapy through a subcutaneous formulation.
• Spesolimab now carries approvals across the US, EU, Japan, and China, giving it the broadest global footprint of any GPP-specific therapy to date, and in July 2025, Boehringer Ingelheim and LEO Pharma entered a global license agreement to broaden access and continue development.
• Ahead of the IL-36 era, clinicians leaned on conventional systemic agents, corticosteroids, acitretin, cyclosporine, and methotrexate, largely repurposed from plaque psoriasis, often with inconsistent flare control and tolerability challenges.
• China's market dynamics stand apart: alongside NMPA approvals, prior expanded-access programs helped build real-world familiarity with IL-36 blockade ahead of formal reimbursement pathways, a nuance the report examines in country-specific detail.

Key Market Drivers/Trends
• A widening biologic class: the shift from zero targeted options to a multi-drug IL-36 antagonist category within a few years is reshaping how physicians think about first-line versus maintenance therapy.
• Regulatory catalysts on the calendar: imsidolimab's December 2026 PDUFA date is a near-term event that could immediately alter competitive share dynamics in the US market.
• Rising diagnostic clarity: genetic testing for IL36RN and related variants is increasingly informing not just diagnosis but also treatment selection and prognosis discussions with patients.
• Global access expansion: spesolimab's spread across all 8MM, combined with new commercial partnerships, signals growing payer and health-system readiness to fund high-cost rare-disease biologics.
• China as a market to watch: parallel regulatory movement and prior patient-access experience make China a disproportionately important market within the 8MM basket for this indication.

Translate these macro drivers into a competitive advantage. Request the Thelansis Generalized Pustular Psoriasis sample report to unlock granular pipeline analysis, deal tracking, and market forecasts: https://thelansis.com/reports/generalized-pustular-psoriasis-gpp-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpp_mo

Key Unmet Need & KOL Expectations
• Despite recent progress, GPP remains under-recognized outside specialist dermatology and rare-disease centers, contributing to diagnostic delay during acute, high-risk flares.
• KOLs continue to flag a need for therapies offering faster onset of pustular clearance, simplified dosing for both flare and maintenance settings, and stronger long-term safety data in adolescent populations.
• Experts also point to gaps in standardized flare-severity scoring and consistent treatment algorithms across geographies, an issue the report's KOL interviews and physician survey data speak to directly.
• There is a growing appetite for target product profiles that combine rapid flare resolution with durable, well-tolerated maintenance dosing, a bar future entrants will be measured against.

Commercial Opportunity
• With a second IL-36 antagonist approaching a regulatory decision and global access to first-in-class therapy still expanding, the GPP market is entering a genuinely competitive phase for the first time.
• Thelansis's report delivers a 10-year (2026-2036), patient-based forecast validated through top-down sales modeling, giving commercial and forecasting teams a defensible basis for portfolio and investment decisions.
• The accompanying deliverables, a detailed report, an automated market forecast model, an interactive epidemiology tool, and executive-ready slides, are built for teams that need to move from insight to internal decision-making quickly.
• Coverage spans all 8 major markets (US, EU5, Japan, China), with country-level nuance on regulatory status, pricing dynamics, and access pathways.

Access the complete Generalized Pustular Psoriasis (GPP) market outlook and forecast report to explore the evolving market and future commercial opportunities: https://thelansis.com/reports/generalized-pustular-psoriasis-gpp-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpp_mo

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.